Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) FCF Margin (2017 - 2025)

Sutro Biopharma's FCF Margin history spans 9 years, with the latest figure at 394.47% for Q3 2025.

  • For Q3 2025, FCF Margin rose 37248.0% year-over-year to 394.47%; the TTM value through Sep 2025 reached 209.42%, down 13641.0%, while the annual FY2024 figure was 309.81%, 23439.0% down from the prior year.
  • FCF Margin for Q3 2025 was 394.47% at Sutro Biopharma, down from 59.28% in the prior quarter.
  • Across five years, FCF Margin topped out at 258.94% in Q3 2022 and bottomed at 1191.4% in Q1 2025.
  • The 5-year median for FCF Margin is 315.01% (2023), against an average of 310.05%.
  • The largest annual shift saw FCF Margin soared 67947bps in 2022 before it plummeted -69027bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 226.37% in 2021, then crashed by -39bps to 315.47% in 2022, then surged by 103bps to 8.87% in 2023, then crashed by -5460bps to 475.26% in 2024, then rose by 17bps to 394.47% in 2025.
  • Per Business Quant, the three most recent readings for STRO's FCF Margin are 394.47% (Q3 2025), 59.28% (Q2 2025), and 1191.4% (Q1 2025).